Comparative Risk of Hospitalized Infection Associated with Biologic Agents in Rheumatoid Arthritis Patients Enrolled in Medicare

Arthritis and Rheumatology

Volumn 68, Issue 1, 2016, Pages 56-66

  Yun, Huifeng ^a   Xie, Fenglong ^a   Delzell, Elizabeth ^a   Levitan, Emily B ^a   Chen, Lang ^a   Lewis, James D ^b   Saag, Kenneth G ^a   Beukelman, Timothy ^a   Winthrop, Kevin L ^c   Baddley, John W ^a   Curtis, Jeffrey R ^a  

^a University of Alabama at Birmingham   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ADALIMUMAB; BIOLOGICAL PRODUCT; CERTOLIZUMAB PEGOL; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GOLIMUMAB; INFLIXIMAB; METHOTREXATE; PREDNISONE; RITUXIMAB; TOCILIZUMAB; TUMOR NECROSIS FACTOR INHIBITOR; ANTIRHEUMATIC AGENT; MONOCLONAL ANTIBODY;

ADULT; AGED; ARTICLE; BACTEREMIA; COHORT ANALYSIS; COMPARATIVE STUDY; DRUG INDUCED DISEASE; FEMALE; FOLLOW UP; HOSPITALIZED INFECTION; HUMAN; INCIDENCE; INFECTION; INFECTION RATE; INFECTION RISK; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MEDICAID; MEDICARE; MIDDLE AGED; PNEUMONIA; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; SEPTICEMIA; SKIN INFECTION; SOFT TISSUE INFECTION; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; ARTHRITIS, RHEUMATOID; HOSPITALIZATION; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; SEPSIS; SOFT TISSUE INFECTIONS; STATISTICS AND NUMERICAL DATA; UNITED STATES; URINARY TRACT INFECTIONS;

ABATACEPT; ADALIMUMAB; AGED; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL PRODUCTS; CERTOLIZUMAB PEGOL; COHORT STUDIES; ETANERCEPT; FEMALE; HOSPITALIZATION; HUMANS; INFECTION; INFLIXIMAB; LENGTH OF STAY; MALE; MEDICARE; MIDDLE AGED; PNEUMONIA; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK FACTORS; RITUXIMAB; SEPSIS; SOFT TISSUE INFECTIONS; UNITED STATES; URINARY TRACT INFECTIONS;

EID: 84952034864     PISSN: 23265191     EISSN: 23265205     Source Type: Journal    
DOI: 10.1002/art.39399     Document Type: Article

References (48)

1. Furst DE., The risk of infections with biologic therapies for rheumatoid arthritis. Semin Arthritis Rheum 2010; 39: 327-46.
2. Curtis JR, Singh JA., Use of biologics in rheumatoid arthritis: current and emerging paradigms of care. Clin Ther 2011; 33: 679-707.
3. Ruderman EM., Overview of safety of non-biologic and biologic DMARDs. Rheumatology (Oxford) 2012; 51 Suppl 6: vi37-43.
4. Keystone EC, Kavanaugh AF, Sharp JT, Tannenbaum H, Hua Y, Teoh LS, et al., Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum 2004; 50: 1400-11.
5. St.Clair EW, van der Heijde DM, Smolen JS, Maini RN, Bathon JM, Emery P, et al, for the Active-Controlled Study of Patients Receiving Infliximab for the Treatment of Rheumatoid Arthritis of Early Onset Study Group. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum 2004; 50: 3432-43.
6. Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V., Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006; 295: 2275-85.
7. Singh JA, Wells GA, Christensen R, Tanjong Ghogomu E, Maxwell L, Macdonald JK, et al., Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database Syst Rev 2011: CD008794.
8. Klareskog L, van der Heijde D, de Jager JP, Gough A, Kalden J, Malaise M, et al., Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 2004; 363: 675-81.
9. Van Riel PL, Taggart AJ, Sany J, Gaubitz M, Nab HW, Pedersen R, et al., Efficacy and safety of combination etanercept and methotrexate versus etanercept alone in patients with rheumatoid arthritis with an inadequate response to methotrexate: the ADORE study. Ann Rheum Dis 2006; 65: 1478-83.
10. Maini RN, Breedveld FC, Kalden JR, Smolen JS, Furst D, Weisman MH, et al, for the Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. Arthritis Rheum 2004; 50: 1051-65.
11. Weinblatt ME, Keystone EC, Furst DE, Moreland LW, Weisman MH, Birbara CA, et al., Adalimumab, a fully human anti-tumor necrosis factor α monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 2003; 48: 35-45.
12. Kay J, Matteson EL, Dasgupta B, Nash P, Durez P, Hall S, et al., Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: a randomized, double-blind, placebo-controlled, dose-ranging study. Arthritis Rheum 2008; 58: 964-75.
13. Fleischmann R, Vencovsky J, van Vollenhoven RF, Borenstein D, Box J, Coteur G, et al., Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study. Ann Rheum Dis 2009; 68: 805-11.
14. Kremer JM, Genant HK, Moreland LW, Russell AS, Emery P, Abud-Mendoza C, et al., Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial. Ann Intern Med 2006; 144: 865-76.
15. Weinblatt M, Combe B, Covucci A, Aranda R, Becker JC, Keystone E., Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: a one-year randomized, placebo-controlled study. Arthritis Rheum 2006; 54: 2807-16.
16. Emery P, Fleischmann R, Filipowicz-Sosnowska A, Schechtman J, Szczepanski L, Kavanaugh A, et al, for the DANCER Study Group. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIb randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum 2006; 54: 1390-400.
17. Cohen SB, Emery P, Greenwald MW, Dougados M, Furie RA, Genovese MC, et al, for the REFLEX Trial Group. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006; 54: 2793-806.
18. Maini RN, Taylor PC, Szechinski J, Pavelka K, Broll J, Balint G, et al, for the CHARISMA Study Group. Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum 2006; 54: 2817-29.
19. Grijalva CG, Chen L, Delzell E, Baddley JW, Beukelman T, Winthrop KL, et al., Initiation of tumor necrosis factor-α antagonists and the risk of hospitalization for infection in patients with autoimmune diseases. JAMA 2011; 306: 2331-9.
20. Curtis JR, Patkar N, Xie A, Martin C, Allison JJ, Saag M, et al., Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor α antagonists. Arthritis Rheum 2007; 56: 1125-33.
21. Curtis JR, Yang S, Patkar NM, Chen L, Singh JA, Cannon GW, et al., Risk of hospitalized bacterial infections associated with biologic treatment among US veterans with rheumatoid arthritis. Arthritis Care Res (Hoboken) 2014; 66: 990-7.
22. Listing J, Strangfeld A, Kary S, Rau R, von Hinueber U, Stoyanova-Scholz M, et al., Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis Rheum 2005; 52: 3403-12.
23. Dixon WG, Symmons DP, Lunt M, Watson KD, Hyrich KL, British Society for Rheumatology Biologics Register Control Centre Consortium, et al, on behalf of the British Society for Rheumatology Biologics Register. Serious infection following anti-tumor necrosis factor α therapy in patients with rheumatoid arthritis: lessons from interpreting data from observational studies. Arthritis Rheum 2007; 56: 2896-904.
24. Dixon WG, Watson K, Lunt M, Hyrich KL, British Society for Rheumatology Biologics Register Control Centre Consortium, Silman AJ, et al, on behalf of the British Society for Rheumatology Biologics Register. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 2006; 54: 2368-76.
25. Galloway JB, Mercer LK, Moseley A, Dixon WG, Ustianowski AP, Helbert M, et al., Risk of skin and soft tissue infections (including shingles) in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis 2013; 72: 229-34.
26. Curtis JR, Xie F, Chen L, Baddley JW, Beukelman T, Saag KG, et al., The comparative risk of serious infections among rheumatoid arthritis patients starting or switching biological agents. Ann Rheum Dis 2011; 70: 1401-6.
27. Chronic Conditions Data Warehouse. National CMS Medicare and Medicaid research database. URL: https://www.ccwdata.org/web/guest/about-ccw.
28. Medicare at a glance. Henry J. Kaiser Family Foundation. URL: http://kff.org/medicare/fact-sheet/medicare-at-a-glance-fact-sheet/.
29. Von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP, for the STROBE Initiative. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol 2008; 61: 344-9.
30. Patkar NM, Curtis JR, Teng GG, Allison JJ, Saag M, Martin C, et al., Administrative codes combined with medical records based criteria accurately identified bacterial infections among rheumatoid arthritis patients. J Clin Epidemiol 2009; 62: 321-7, 327.e1-7.
31. Glynn RJ, Gayne JJ, Schneeweiss S., Role of disease risk scores in comparative effectiveness research with emerging therapies. Pharmacoepidemiol Drug Saf 2012; 21 Suppl 2: 138-47.
32. Curtis JR, Xie F, Chen L, Muntner P, Grijalva CG, Spettell C, et al., Use of a disease risk score to compare serious infections associated with anti-tumor necrosis factor therapy among high- versus lower-risk rheumatoid arthritis patients. Arthritis Care Res (Hoboken) 2012; 64: 1480-9.
33. Doran MF, Crowson CS, Pond GR, O'Fallon WM, Gabriel SE., Predictors of infection in rheumatoid arthritis. Arthritis Rheum 2002; 46: 2294-300.
34. Lin DY, Wei LJ., The robust inference for the Cox proportional hazards model. J Am Stat Assoc 1989; 84: 1074-8.
35. Singh JA, Christensen R, Wells GA, Suarez-Almazor ME, Buchbinder R, Lopez-Olivo MA, et al., A network meta-analysis of randomized controlled trials of biologics for rheumatoid arthritis: a Cochrane overview [published erratum appears in CMAJ 2010;182:806]. CMAJ 2009; 181: 787-96.
36. Singh JA, Christensen R, Wells GA, Suarez-Almazor ME, Buchbinder R, Lopez-Olivo MA, et al., Biologics for rheumatoid arthritis: an overview of Cochrane reviews. Cochrane Database Syst Rev 2009: CD007848.
37. Capell HA., Disease modifying antirheumatic drugs: longterm safety issues. J Rheumatol Suppl 2001; 62: 10-5.
38. Curtis JR, Xi J, Patkar N, Xie A, Saag KG, Martin C., Drug-specific and time-dependent risks of bacterial infection among patients with rheumatoid arthritis who were exposed to tumor necrosis factor α antagonists. Arthritis Rheum 2007; 56: 4226-7.
39. Dixon WG, Hyrich KL, Watson KD, Lunt M, Galloway J, Ustianowski A, et al, on behalf of the BSR Biologics Register. Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR). Ann Rheum Dis 2010; 69: 522-8.
40. Johnston SS, Turpcu A, Shi N, Fowler R, Chu BC, Alexander K., Risk of infections in rheumatoid arthritis patients switching from anti-TNF agents to rituximab, abatacept, or another anti-TNF agent, a retrospective administrative claims analysis. Semin Arthritis Rheum 2013; 43: 39-47.
41. Schneeweiss S, Setoguchi S, Weinblatt ME, Katz JN, Avorn J, Sax PE, et al., Anti-tumor necrosis factor α therapy and the risk of serious bacterial infections in elderly patients with rheumatoid arthritis. Arthritis Rheum 2007; 56: 1754-64.
42. Dewedar AM, Shalaby MA, Al-Homaid S, Mahfouz AM, Shams OA, Fathy A., Lack of adverse effect of anti-tumor necrosis factor-α biologics in treatment of rheumatoid arthritis: 5 years follow-up. Int J Rheum Dis 2012; 15: 330-5.
43. Keyser FD., Choice of biologic therapy for patients with rheumatoid arthritis: the infection perspective. Curr Rheumatol Rev 2011; 7: 77-87.
44. Van Dartel SA, Fransen J, Kievit W, Flendrie M, den Broeder AA, Visser H, et al., Difference in the risk of serious infections in patients with rheumatoid arthritis treated with adalimumab, infliximab and etanercept: results from the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry. Ann Rheum Dis 2013; 72: 895-900.
45. Strangfeld A, Eveslage M, Schneider M, Bergerhausen HJ, Klopsch T, Zink A, et al., Treatment benefit or survival of the fittest: what drives the time-dependent decrease in serious infection rates under TNF inhibition and what does this imply for the individual patient? Ann Rheum Dis 2011; 70: 1914-20.
46. Curtis JR, Martin C, Saag KG, Patkar NM, Kramer J, Shatin D, et al., Confirmation of administrative claims-identified opportunistic infections and other serious potential adverse events associated with tumor necrosis factor α antagonists and disease-modifying antirheumatic drugs. Arthritis Rheum 2007; 57: 343-6.
47. Curtis JR, Saag KG, Martin C, Patkar N, Shatin D, Kramer JM, et al., Validation of claims-identified serious adverse events in rheumatoid arthritis and Crohn's disease patients [poster]. Arthritis Rheum 2005; 52: 4085.
48. Yun H, Xie F, Delzell E, Chen L, Levitan EB, Lewis JD, et al., Risk of hospitalised infection in rheumatoid arthritis patients receiving biologics following a previous infection while on treatment with anti-TNF therapy. Ann Rheum Dis 2015; 74: 1065-71.